Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 4 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Monopar Therapeutics changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 12 | 6 | −6 |
| SharesConverted for a 1-for-5 split | 83.6K | 15.7K | −67.9K (−81.2%) |
| Value | $310.1K | $105.9K | −$204.2K (−65.9%) |
New holders (1)
Institutions that held Monopar Therapeutics at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 512 | $3.45K | 0.00% |
Sold out (7)
Institutions that held Monopar Therapeutics at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Millennium Management LLC | 194,298 | $145.3K |
| Two Sigma Securities, LLC | 47,058 | $34.4K |
| Vanguard Group Inc | 45,167 | $33.0K |
| Gerber, LLC | 28,005 | $20.4K |
| Virtu Financial LLC | 18,840 | $14.0K |
| Rappaport Reiches Capital Management, LLC | 10,695 | $7.81K |
| Tower Research Capital LLC (TRC) | 7,922 | $5.78K |